blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2819697

EP2819697 - ANTIBODIES TO MATRIX METALLOPROTEINASE 9 [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.09.2017
Database last updated on 30.09.2024
FormerExamination is in progress
Status updated on  17.02.2017
Most recent event   Tooltip01.09.2017Application deemed to be withdrawnpublished on 04.10.2017  [2017/40]
Applicant(s)For all designated states
Gilead Biologics, Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
[2015/02]
Inventor(s)01 / ADAMKEWICZ, Joanne I.
333 Lakeside Drive
Foster City, CA 94404 / US
02 / SMITH, Victoria
333 Lakeside Drive
Foster City, CA 94404 / US
03 / THAI, Zung
333 Lakeside Drive
Foster City, CA 94404 / US
04 / HAWKINS, Michael J.
550 Davis Street, 14
San Francisco, CA 94111 / US
 [2015/02]
Representative(s)Schnappauf, Georg, et al
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[N/P]
Former [2015/02]Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date13754254.428.02.2013
WO2013US28456
Priority number, dateWO2012US2716029.02.2012         Original published format: PCT/US2012/027160
US201261605181P29.02.2012         Original published format: US 201261605181 P
US201361755444P22.01.2013         Original published format: US 201361755444 P
[2015/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013130905
Date:06.09.2013
Language:EN
[2013/36]
Type: A1 Application with search report 
No.:EP2819697
Date:07.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 06.09.2013 takes the place of the publication of the European patent application.
[2015/02]
Search report(s)International search report - published on:KR06.09.2013
(Supplementary) European search report - dispatched on:EP04.02.2016
ClassificationIPC:C07K16/40, C12N9/64, A61K39/395
[2015/47]
CPC:
C07K16/40 (EP,CN,US); A61K31/513 (EP,US); A61K39/3955 (EP,US);
A61K45/06 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P11/06 (EP); A61P19/02 (EP); A61P21/00 (EP);
A61P21/02 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/04 (EP); A61P37/06 (EP); A61P37/08 (EP);
A61P43/00 (EP); A61K2039/505 (EP,CN,US); A61K2039/507 (EP,US);
C07K2317/24 (EP,CN,US) (-)
C-Set:
A61K31/513, A61K2300/00 (EP,US);
A61K39/3955, A61K2300/00 (US,EP)
Former IPC [2015/02]A61K39/395, A61K38/17, A61K38/16, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/02]
Extension statesBA26.09.2014
ME26.09.2014
TitleGerman:ANTIKÖRPER GEGEN MATRIX-METALLOPROTEINASE-9[2015/02]
English:ANTIBODIES TO MATRIX METALLOPROTEINASE 9[2015/02]
French:ANTICORPS DIRIGÉS CONTRE LA MÉTALLOPROTÉINASE 9 DE MATRICE[2015/02]
Entry into regional phase26.09.2014National basic fee paid 
26.09.2014Search fee paid 
26.09.2014Designation fee(s) paid 
26.09.2014Examination fee paid 
Examination procedure26.09.2014Examination requested  [2015/02]
02.09.2016Amendment by applicant (claims and/or description)
19.10.2016Despatch of a communication from the examining division (Time limit: M06)
03.05.2017Application deemed to be withdrawn, date of legal effect  [2017/40]
29.05.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2017/40]
Divisional application(s)EP17168528.2
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.10.2016
Fees paidRenewal fee
26.02.2015Renewal fee patent year 03
26.02.2016Renewal fee patent year 04
27.02.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2007094842  (GENENTECH INC [US], et al) [X] 1,3,4,7-10 * seq ID 413;; claims 1-115 * * in particular * * abstract * * figure 11A; sequence 413 *;
 [X]WO2008154439  (IRM LLC, et al) [X] 1,3,4,9,10 * the whole document * * in particular * * abstract * * claim 4; sequence 59 *;
 [X]WO2009111450  (DYAX CORP [US], et al) [X] 1,3-10 * the whole document * * in particular * * abstract * * page 1, line 14 - page 12, line 21 * * figures 1-10; examples 1-16; claims 1-53 *;
 [A]WO2010059543  (MERCK SHARP & DOHME [US], et al) [A] 1-10 * the whole document * * in particular * * abstract * * page 239; sequence 250 *;
 [XP]WO2012027721  (GILEAD BIOLOGICS INC [US], et al) [XP] 1-10* Mouse AB0041;; claims 1-23 *;
 [Y]  - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20031101), vol. 21, no. 11, doi:10.1016/J.TIBTECH.2003.08.007, ISSN 0167-7799, pages 484 - 490, XP004467495 [Y] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.tibtech.2003.08.007
 [Y]  - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, (19960901), vol. 2, no. 3, doi:10.1016/S1380-2933(96)00045-0, ISSN 1380-2933, pages 169 - 179, XP004070292 [Y] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1380-2933(96)00045-0
 [A]  - CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, (20060407), vol. 6, doi:10.1038/NRI1837, ISSN 1474-1733, pages 343 - 357, XP007901440 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1038/nri1837
 [A]  - WARK K L ET AL, "Latest technologies for the enhancement of antibody affinity", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 5-6, doi:10.1016/J.ADDR.2006.01.025, ISSN 0169-409X, (20060807), pages 657 - 670, (20060807), XP024892147 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.addr.2006.01.025
International search[A]US2009208510  (SAGI IRIT [IL], et al);
 [A]US2009311245  (DEVY LAETITIA [US], et al);
 [A]  - MARTENS, E. ET AL., "A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains", BIOCHIMICA ET BIOPHYSICA ACTA, (2007), vol. 1770, pages 178 - 186, XP005818408

DOI:   http://dx.doi.org/10.1016/j.bbagen.2006.10.012
 [A]  - HU, J. ET AL., "Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody", BIOCHEMICAL PHARMACOLOGY, (2004), vol. 67, pages 1001 - 1009, XP055042352

DOI:   http://dx.doi.org/10.1016/j.bcp.2003.10.030
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.